Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.
Previously we reported a broadly HIV-1 neutralizing mini-antibody (Fab 3674) of modest potency that was derived from a human non-immune phage library by panning against the chimeric gp41-derived construct N(CCG)-gp41. This construct presents the N-heptad repeat of the gp41 ectodomain as a stable, helical, disulfide-linked trimer that extends in helical phase from the six-helix bundle of gp41. In this paper, Fab 3674 was subjected to affinity maturation against the N(CCG)-gp41 antigen by targeted diversification of the CDR-H2 loop to generate a panel of Fabs with diverse neutralization activity. Three affinity-matured Fabs selected for further study, Fabs 8060, 8066 and 8068, showed significant increases in both potency and breadth of neutralization against HIV-1 pseudotyped with envelopes of primary isolates from the standard subtype B and C HIV-1 reference panels. The parental Fab 3674 is 10-20-fold less potent in monovalent than bivalent format over the entire B and C panels of HIV-1 pseudotypes. Of note is that the improved neutralization activity of the affinity-matured Fabs relative to the parental Fab 3674 was, on average, significantly greater for the Fabs in monovalent than bivalent format. This suggests that the increased avidity of the Fabs for the target antigen in bivalent format can be partially offset by kinetic and/or steric advantages afforded by the smaller monovalent Fabs. Indeed, the best affinity-matured Fab (8066) in monovalent format ( approximately 50 kDa) was comparable in HIV-1 neutralization potency to the parental Fab 3674 in bivalent format ( approximately 120 kDa) across the subtype B and C reference panels.
Gustchina
Elena
E
Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, USA.
Louis
John M
JM
Frisch
Christian
C
Ylera
Francisco
F
Lechner
Annette
A
Bewley
Carole A
CA
Clore
G Marius
GM
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology*; D000915:Antibody Affinity; D019020:Directed Molecular Evolution; D015483:HIV Antibodies / Q000235:genetics / Q000276:immunology*; D015700:HIV Envelope Protein gp41 / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D020128:Inhibitory Concentration 50; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D019151:Peptide Library; D016415:Sequence Alignment
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41; D019151:Peptide Library; C514787:gp41 protein, Human immunodeficiency virus 1
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15613-7
9861018
J Biol Chem. 2005 Apr 1;280(13):12567-72
15657041
Adv Enzyme Regul. 1984;22:27-55
6382953
J Virol. 2002 Jul;76(13):6780-90
12050391
Anal Biochem. 2005 Apr 1;339(1):182-4
15766727
J Virol. 1995 Jul;69(7):4413-22
7769703
Curr Pharm Des. 2004;10(15):1805-25
15180542
Nat Rev Drug Discov. 2004 Mar;3(3):215-25
15031735
AIDS Res Hum Retroviruses. 2003 Feb;19(2):133-44
12639249
J Virol. 2008 Jul;82(14):6869-79
18480433
Nucleic Acids Res. 1994 Dec 25;22(25):5600-7
7838712
Virology. 2008 Jul 20;377(1):170-83
18499210
J Mol Biol. 2008 Feb 29;376(4):1182-200
18191144
Science. 2001 Feb 2;291(5505):884-8
11229405
J Virol. 1996 Sep;70(9):6136-42
8709238
J Virol. 1989 Nov;63(11):4670-5
2677400
Nat Struct Mol Biol. 2006 Aug;13(8):740-7
16862157
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14759-64
16203977
Virology. 2007 Jun 20;363(1):79-90
17306322
J Mol Biol. 2006 Dec 1;364(3):283-9
17010381
Immunol Rev. 1992 Dec;130:151-88
1286869
Curr Opin Biotechnol. 2002 Dec;13(6):598-602
12482520
J Virol. 2006 Apr;80(7):3249-58
16537592
J Virol. 2008 Oct;82(20):10032-41
18667502
J Virol. 2005 Aug;79(16):10103-7
16051803
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54
12444251
J Mol Biol. 2005 Nov 11;353(5):945-51
16216270
EMBO J. 1998 Aug 17;17(16):4572-84
9707417
Cell. 1997 Apr 18;89(2):263-73
9108481
Eur J Biochem. 1981 Mar 16;115(1):207-16
7227366
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10537-41
1438243
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4
7937889
J Virol. 1998 Dec;72(12):10213-7
9811763
Annu Rev Immunol. 1999;17:657-700
10358771
J Biol Chem. 2001 Aug 3;276(31):29485-9
11418583
J Biol Chem. 2002 Apr 19;277(16):14238-45
11859089
J Biol Chem. 2003 Oct 3;278(40):38194-205
12842902
Biol Chem. 2006 Jul;387(7):995-1003
16913849
Protein Sci. 2008 Dec;17(12):2091-100
18802030
J Biol Chem. 2003 May 30;278(22):20278-85
12654905
Nature. 1997 May 22;387(6631):426-30
9163431
Nature. 1993 Sep 9;365(6442):113
8371754
Cell. 1998 May 29;93(5):681-4
9630213
J Virol. 2007 Dec;81(23):12946-53
17898046
Nat Struct Biol. 1998 Apr;5(4):276-9
9546217
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92
11572974
J Virol. 2005 Aug;79(16):10108-25
16051804
J Virol. 2000 Nov;74(21):10074-80
11024136
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12303-8
9356444
Biochim Biophys Acta. 2003 Jul 11;1614(1):36-50
12873764
J Virol. 2006 Feb;80(3):1414-26
16415019
J Mol Biol. 2000 Feb 11;296(1):57-86
10656818
Mol Immunol. 2008 Nov;46(1):135-44
18722015
Cell. 1999 Oct 1;99(1):103-15
10520998
Annu Rev Biochem. 2001;70:777-810
11395423
J Biol Chem. 2006 Sep 1;281(35):25813-21
16803885
AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2037-41
11153086